参麦注射液对局部晚期非小细胞肺癌同步放化疗患者免疫功能的影响

目的 观察参麦注射液对局部晚期非小细胞肺癌同步放化疗患者免疫功能的影响.方法 将80例局部晚期非小细胞肺癌患者随机均分为治疗组和对照组.对照组给予三维适形放疗同步TP(多西他赛+顺铂)方案化疗.治疗组在对照组基础上同时给予参麦注射液治疗.观察两组T细胞亚群变化.结果 两组治疗前CD+3、CD+4、CD+8、CD+4/CD+8和CD+16 CD+56差异均无统计学意义(均P＞0.05).治疗组应用参麦注射液后未出现明显不良反应.结论 参麦注射液联合同步放化疗治疗局部晚期非小细胞肺癌,对提高机体免疫力具有重要作用.

Influence of Shenmai injection on immune function in the treatment of locally advanced non-small cell lung cancer patients with concurrent chemoradiotherapy

Objective To observe the effect of Shenmai injection combined concurrent chemoradiotherapy on immune function in patients with locally advanced non-small cell lung cancer. Methods A total of 80 patients with locally advanced non-small cell lung cancer were randomly divided into treatment group and control group. In treat- ment group,40 patients received simultaneous three-dimensional conformal radiotherapy combined with TP（ docetaxel ＋ cisplatin） chemotherapy,while given Shenmai injection in the process of concurrent chemoradiotherapy. In control group,40 patients only received chemoradiotherapy. The changes of T cell subsets were observed b~tween the two groups. Results It showed no significant differences in percentages of CD3＋ , CD4 ＋, CD16＋ CD56＋ and CD4＋/CD8＋ ratio be- tween two groups pre-treatment （ all P 〉 0. 05 ）. There were no significant adverse reactions occurred after received Shenmai injection in treatment group. Conclusion It play an important role in improving immune function of patients with locally advanced non-small cell lung cancer who received Shenmai injection combined concurrent chemoradio- therapy.